Kistler Tiffany Companies LLC cut its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 1.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,913 shares of the medical research company’s stock after selling 141 shares during the period. Amgen comprises about 1.2% of Kistler Tiffany Companies LLC’s portfolio, making the stock its 15th biggest position. Kistler Tiffany Companies LLC’s holdings in Amgen were worth $2,514,000 at the end of the most recent quarter.
A number of other large investors have also modified their holdings of the business. Deane Retirement Strategies Inc. increased its stake in Amgen by 0.6% during the fourth quarter. Deane Retirement Strategies Inc. now owns 9,838 shares of the medical research company’s stock worth $1,915,000 after purchasing an additional 60 shares during the period. Arlington Partners LLC increased its stake in Amgen by 86.7% during the fourth quarter. Arlington Partners LLC now owns 140 shares of the medical research company’s stock worth $27,000 after purchasing an additional 65 shares during the period. Pure Financial Advisors Inc. increased its stake in Amgen by 8.8% during the fourth quarter. Pure Financial Advisors Inc. now owns 1,432 shares of the medical research company’s stock worth $279,000 after purchasing an additional 116 shares during the period. Murphy Capital Management Inc. increased its stake in Amgen by 2.3% during the third quarter. Murphy Capital Management Inc. now owns 11,285 shares of the medical research company’s stock worth $2,339,000 after purchasing an additional 254 shares during the period. Finally, Fairfield Bush & CO. grew its position in shares of Amgen by 0.8% during the second quarter. Fairfield Bush & CO. now owns 33,934 shares of the medical research company’s stock worth $6,264,000 after buying an additional 260 shares in the last quarter. Institutional investors own 76.88% of the company’s stock.
AMGN traded down $3.06 on Monday, reaching $197.50. The company’s stock had a trading volume of 113,879 shares, compared to its average volume of 3,355,345. The company has a quick ratio of 2.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.05. The company has a market capitalization of $127.68 billion, a price-to-earnings ratio of 15.70, a price-to-earnings-growth ratio of 2.05 and a beta of 1.32. Amgen, Inc. has a fifty-two week low of $163.31 and a fifty-two week high of $210.19.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, October 30th. The medical research company reported $3.69 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.45 by $0.24. The firm had revenue of $5.90 billion during the quarter, compared to the consensus estimate of $5.78 billion. Amgen had a return on equity of 54.14% and a net margin of 9.44%. The firm’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same period in the prior year, the company posted $3.27 earnings per share. On average, equities analysts anticipate that Amgen, Inc. will post 14.24 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 8th. Shareholders of record on Friday, February 15th will be paid a $1.45 dividend. The ex-dividend date is Thursday, February 14th. This represents a $5.80 dividend on an annualized basis and a yield of 2.94%. This is a boost from Amgen’s previous quarterly dividend of $1.32. Amgen’s payout ratio is currently 41.97%.
In other Amgen news, SVP Cynthia M. Patton sold 1,777 shares of the business’s stock in a transaction that occurred on Thursday, November 29th. The stock was sold at an average price of $202.88, for a total value of $360,517.76. Following the completion of the sale, the senior vice president now owns 23,090 shares in the company, valued at $4,684,499.20. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Tyler Jacks sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, December 6th. The shares were sold at an average price of $195.41, for a total value of $3,908,200.00. Following the completion of the sale, the director now owns 28,979 shares of the company’s stock, valued at approximately $5,662,786.39. The disclosure for this sale can be found here. 0.27% of the stock is currently owned by insiders.
A number of equities analysts have recently commented on AMGN shares. Citigroup boosted their price objective on Amgen from $200.00 to $204.00 and gave the stock a “neutral” rating in a research report on Thursday, November 1st. Zacks Investment Research raised Amgen from a “hold” rating to a “buy” rating and set a $225.00 price objective for the company in a research report on Monday. Goldman Sachs Group reissued a “buy” rating and set a $232.00 price objective on shares of Amgen in a research report on Tuesday, December 4th. Royal Bank of Canada lowered their price objective on Amgen to $182.00 and set a “market perform” rating for the company in a research report on Wednesday, October 31st. Finally, reissued a “buy” rating and set a $224.00 price objective on shares of Amgen in a research report on Monday, October 1st. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $205.50.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by Enterprise Leader and is the sole property of of Enterprise Leader. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://theenterpriseleader.com/2019/01/14/kistler-tiffany-companies-llc-sells-141-shares-of-amgen-inc-amgn.html.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Recommended Story: Outstanding Shares and The Effect on Share Price
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.